Trending...
- Southern Soul Artist Moe Z Releases New Single 'Set It Out' Distributed by Morris Day Entertainment
- Cal State LA secures funding for two artificial intelligence projects from CSU
- Skool Alternatives Reddit: Skool vs Circle vs Whop - Did you join one yet?
SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a purchaser of MEI Pharma, Inc. (NASDAQ: MEIP) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between August 2, 2017 and July 1, 2020. MEI Pharma is a late-stage pharmaceutical company that focuses on the development of various therapies for the treatment of cancer. One of MEI Pharma's drug candidates include Pracinostat, an oral histone deacetylase ("HDAC") inhibitor.
If you suffered a loss due to MEI Pharma's misconduct, click here.
MEI Pharma, Inc. (MEIP) Accused of Misleading Shareholders
More on The Californer
According to the complaint, in 2016 MEI Pharma entered into an exclusive license agreement with Helsinn Healthcare SA, a Swiss pharmaceutical corporation ("Helsinn"), in which Helsinn would develop, manufacture, and commercialize Pracinostat while MEI Pharma received $20 million for the grant rights with the potential to receive up to $444 million in regulatory and sales-based milestones along with royalty payments. In August 2017, MEI Pharma and Helsinn announced the beginning of the Phase 3 Pracinostat trial after "the potential of [P]racinostat … was demonstrated in the Phase 2 study," touting that the "well-powered, rigorously designed Phase 3 study" would bring Pracinostat one step closer to becoming a treatment for those with AML. In later SEC reports and filings, MEI Pharma continued to tout the "potency" and median overall survival of patients in the Phase 2 trial of Pracinostat. Despite the Company's positive representations of the drug, on July 2, 2020, MEI Pharma announced it was discontinuing the Phase 3 Pracinostat trial, revealing that an interim futility analysis of the study "demonstrated [Pracinostat] was unlikely to meet the primary endpoint of overall survival compared to the control group." On this news, MEI Pharma's shares fell 18% to close at $3.49 per share and has yet to recover.
More on The Californer
MEI Pharma, Inc. (MEIP) Shareholders Have Options
Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form
Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against MEI Pharma settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
If you suffered a loss due to MEI Pharma's misconduct, click here.
MEI Pharma, Inc. (MEIP) Accused of Misleading Shareholders
More on The Californer
- Yvette Kendall Secures $6 Million Deal with The Sessions Studios for Horror Thriller, "NORTH"
- Buy The Crave Launches Premium Creatine and Natural Wellness Supplements for Modern Lifestyles
- Long Beach Parks, Recreation and Marine's Homeland Cultural Center Presents DanceFest at Cesar Chavez Park Amphitheater on August 16
- Sisu, a Portrait of Grit, Connection and Triumph, Premieres on Documentary Showcase
- New Liz Taylor Book Coming Soon: Chasing Elizabeth Taylor
According to the complaint, in 2016 MEI Pharma entered into an exclusive license agreement with Helsinn Healthcare SA, a Swiss pharmaceutical corporation ("Helsinn"), in which Helsinn would develop, manufacture, and commercialize Pracinostat while MEI Pharma received $20 million for the grant rights with the potential to receive up to $444 million in regulatory and sales-based milestones along with royalty payments. In August 2017, MEI Pharma and Helsinn announced the beginning of the Phase 3 Pracinostat trial after "the potential of [P]racinostat … was demonstrated in the Phase 2 study," touting that the "well-powered, rigorously designed Phase 3 study" would bring Pracinostat one step closer to becoming a treatment for those with AML. In later SEC reports and filings, MEI Pharma continued to tout the "potency" and median overall survival of patients in the Phase 2 trial of Pracinostat. Despite the Company's positive representations of the drug, on July 2, 2020, MEI Pharma announced it was discontinuing the Phase 3 Pracinostat trial, revealing that an interim futility analysis of the study "demonstrated [Pracinostat] was unlikely to meet the primary endpoint of overall survival compared to the control group." On this news, MEI Pharma's shares fell 18% to close at $3.49 per share and has yet to recover.
More on The Californer
- City of Long Beach Experienced a 4% Decrease in Fireworks-Related Reports on July 4
- The Blue Luna Encourages Local Schools to Take Steps to Enhance Safety for Students and Staff
- Wise Business Plans Launches Turnkey Startup Packages to Help Entrepreneurs Start and Scale
- CarSeek Re-Launch: A New Look, A Better Experience for Car Buyers
- California: Governor Newsom provides $11 million to organizations helping underserved job seekers find training and employment
MEI Pharma, Inc. (MEIP) Shareholders Have Options
Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form
Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against MEI Pharma settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
Filed Under: Business
0 Comments
Latest on The Californer
- First Partner highlights apprenticeship program helping underrepresented youth break into careers in California's iconic entertainment industry
- Stuck Doing Math or Figuring Out Life's Numbers? Calculator.now Makes It Stupidly Simple
- Cal State LA secures funding for two artificial intelligence projects from CSU
- Colbert Packaging Announces WBENC Recognition
- New Mobile Car Detailing Platform Connects Drivers with On-Demand Local Pros
- Over the past three months, California seized $476 million worth of unlicensed cannabis products
- California scores more clean energy records: 9 in 10 days this year partially powered by 100% clean energy
- "Mobile Suit Gundam" Takes Over San Diego Comic-Con 2025
- DivX Empowers Media Enthusiasts with Free Expert Guides for Advanced MP4 Management
- Assent Expands Executive Team to Accelerate Global Growth & Innovation
- The World's Largest Green Economic Revolution Emerges as Nature, Tech, and Finance Converge
- Hamilton Zanze Sponsors the Acquisition of Two Garden-Style Communities in Reno Area
- Meet a Scientologist Captures Greece's Timeless Beauty with Videographer Lambros Malamas
- Vinnetwork Unveils Decentralized AI Platform with Vinnetwork(VIN) Token to Challenge Tech Giants' Data Monopoly
- Moovs Launches Advanced Contact Center Solution for Large-Scale Transportation Operations
- Centennial Flyers to Become Colorado's First Launch Customer for All-Electric B23 Energic Aircraft
- Second Annual Artists' Rights Advocate Award to Be Presented at The Comedy Store on July 17th
- Pyro Marketing Opens New Digital Marketing Company in Saint Petersburg to Power Growth for Fitness and Ecommerce Brands
- Dr. John Salerno of Salerno Wellness Introduces Their New Full Body Capsule for Advanced LED Light Therapy Patient Treatments
- Ship Overseas Inc. Expands Specialized Shipping Services